HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STADA Arzneimittel AG

https://www.stada.com/

Latest From STADA Arzneimittel AG

Stada Launches Bevacizumab Biosimilar In EU

Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.

Launches Biosimilars

Stada Sales Increase By 18% In 2020 To Break Through €3bn Barrier

Stada enjoyed double-digit growth for revenues and profitability when adjusted for currency and one-time costs last year, as the privately-owned German firm championed its supply chain investments amid the coronavirus pandemic.

Sales & Earnings Strategy

Stada Launches Medical Cannabis Portfolio

Stada has announced the launch of its medical cannabis portfolio under the brand CannabiStada in Germany. The company will be rolling out both flowers and whole extracts, primarily geared towards chronic pain patients for whom established medications, such as opioids, do not work.

Launches Germany

Who’s Hired? Stada Names New Specialty Head

Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.

Appointments Strategy
See All

Company Information

UsernamePublicRestriction

Register